What is the primary driver behind the significant decrease in reported net income?

The primary driver for the significant decrease in reported net income is the substantial restructuring charges and acquisition-related costs, totaling $280 million for the nine months ended September 27, 2015. These costs are associated with the company's comprehensive operational efficiency program and supply network strategy, aimed at reducing complexity and improving efficiency.

How is the company's adjusted net income different from its reported net income, and what does it indicate?

Adjusted net income excludes items like purchase accounting adjustments, acquisition-related costs, and certain significant items (such as restructuring charges and stand-up costs). The company reports adjusted net income to provide an alternative view of performance, focusing on the core operations. The increase in adjusted net income (15% year-to-date) suggests that, despite the large charges impacting reported net income, the underlying business operations are performing well.

What was the impact of the Abbott Animal Health acquisition?

The acquisition of Abbott Animal Health assets in February 2015 expanded Zoetis's companion animal product portfolio. This acquisition contributed to an 18% operational revenue increase in the companion animal segment during the third quarter of 2015 and was a significant driver of the 15% operational revenue growth in the U.S. segment for the nine-month period.

What are the company's plans regarding operational efficiency and cost reduction?

Zoetis announced a comprehensive operational efficiency program in May 2015. This program includes reducing product complexity, changing selling approaches, exiting certain markets, planning to sell/exit manufacturing sites, and reducing employee positions. The company expects this initiative to generate approximately $300 million in annual cost savings by 2017 and incurred significant charges in 2015 as part of its implementation.

ZTS 10-Q Quarterly Report Q3 FY2015 — Revenue, Net Income, EPS

Summary

Zoetis Inc. reported steady revenue for the nine months ended September 27, 2015, with a slight increase to $3,491 million compared to $3,465 million in the prior year period. However, net income attributable to Zoetis Inc. saw a significant decrease of 31% to $317 million from $457 million in the comparable period, largely due to substantial restructuring charges and acquisition-related costs related to the company's comprehensive operational efficiency program. The company also saw a decrease in diluted EPS to $0.63 from $0.91 year-over-year. Despite the GAAP net income decline, the company highlighted "adjusted net income," which excludes certain charges, showing a 15% increase to $675 million. This adjusted view indicates underlying operational strength. The acquisition of Abbott Animal Health in February 2015 is expected to bolster the companion animal segment. Management is focused on driving operational efficiencies, which are reflected in SG&A and R&D expense reductions, though these initiatives also incurred significant charges in the current period.

Financial Highlights

53 data points

Beta

Revenue

$1.21B

0.7% Gross Margin

Net Income

$190.00M

0.2% Net Margin

EPS (Diluted)

$0.38

Total Assets

$6.69B

Cash & Equivalents

$592.00M

Free Cash Flow

$152.00M

Financial Statements

Beta

Revenue	$1.21B
Cost of Revenue	$421.00M
Gross Profit	$793.00M
SG&A Expenses	$374.00M
Operating Expenses	$928.00M
Interest Expense	$29.00M
Net Income	$190.00M
EPS (Basic)	$0.38
EPS (Diluted)	$0.38
Shares Outstanding (Basic)	499.20M
Shares Outstanding (Diluted)	501.70M

Key Highlights

1Revenue for the nine months ended September 27, 2015, increased slightly to $3,491 million from $3,465 million in the prior year, driven by operational growth of 9%.
2Net income attributable to Zoetis Inc. decreased significantly by 31% to $317 million for the nine-month period, impacted by $280 million in restructuring charges and acquisition-related costs.
3Diluted Earnings Per Share (EPS) declined to $0.63 for the nine-month period from $0.91 in the prior year.
4The company acquired assets of Abbott Animal Health in February 2015, contributing to an 18% operational revenue increase in the companion animal segment for the third quarter.
5Selling, General & Administrative (SG&A) expenses decreased by 3% year-to-date, reflecting cost-reduction initiatives.
6Research and Development (R&D) expenses decreased by 6% year-to-date, also a result of efficiency efforts.
7Zoetis's full-year 2015 guidance anticipates adjusted diluted EPS between $1.70 and $1.74, and adjusted net income between $855 and $875 million, suggesting confidence in underlying operational performance.

Zoetis Inc. Quarterly Report for Q3 Ended Sep 27, 2015

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions